BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31990410)

  • 1. Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
    Schmidt PJ; Hollowell ML; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2020 May; 95(5):492-496. PubMed ID: 31990410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.
    Barman-Aksözen J; C Wiek P; Bansode VB; Koentgen F; Trüb J; Pelczar P; Cinelli P; Schneider-Yin X; Schümperli D; Minder EI
    Dis Model Mech; 2017 Mar; 10(3):225-233. PubMed ID: 28093505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
    Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
    Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity.
    Barman-Aksoezen J; Girelli D; Aurizi C; Schneider-Yin X; Campostrini N; Barbieri L; Minder EI; Biolcati G
    J Inherit Metab Dis; 2017 May; 40(3):433-441. PubMed ID: 28185024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria.
    Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H
    Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.
    Duchartre Y; Petit N; Moya C; Lalanne M; Dubus P; Verneuil Hd; Moreau-Gaudry F; Richard E
    J Hepatol; 2011 Jul; 55(1):162-70. PubMed ID: 21145811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver metabolomics in a mouse model of erythropoietic protoporphyria.
    Wang P; Sachar M; Guo GL; Shehu AI; Lu J; Zhong XB; Ma X
    Biochem Pharmacol; 2018 Aug; 154():474-481. PubMed ID: 29906468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microcytosis in Erythropoietic Protoporphyria.
    Graziadei G; Duca L; Granata F; De Luca G; De Giovanni A; Brancaleoni V; Nava I; Di Pierro E
    Front Physiol; 2022; 13():841050. PubMed ID: 35309058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice.
    Lyoumi S; Abitbol M; Andrieu V; Henin D; Robert E; Schmitt C; Gouya L; de Verneuil H; Deybach JC; Montagutelli X; Beaumont C; Puy H
    Blood; 2007 Jan; 109(2):811-8. PubMed ID: 17003376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria.
    Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X
    Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cimetidine for erythropoietic protoporphyria.
    Heerfordt IM; Lerche CM; Wulf HC
    Photodiagnosis Photodyn Ther; 2022 Jun; 38():102793. PubMed ID: 35245673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat erythropoietic protoporphyria and X-linked protoporphyria.
    Leaf RK; Dickey AK
    Blood; 2023 Jun; 141(24):2921-2931. PubMed ID: 36898083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model.
    Abitbol M; Puy H; Sabaté JM; Guénet JL; Deybach JC; Montagutelli X
    Physiol Res; 2006; 55 Suppl 2():S93-101. PubMed ID: 17298226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria.
    Holme SA; Worwood M; Anstey AV; Elder GH; Badminton MN
    Blood; 2007 Dec; 110(12):4108-10. PubMed ID: 17804693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of iron supplements in individuals with erythropoietic protoporphyria.
    Heerfordt IM; Lerche CM; Philipsen PA; Wulf HC
    Photodiagnosis Photodyn Ther; 2024 May; ():104211. PubMed ID: 38734198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical abnormality in erythropoietic protoporphyria: cause and consequences.
    Bloomer JR; Wang Y; Singhal A; Risheg H
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S36-40. PubMed ID: 16819399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.
    Parker CJ; Desnick RJ; Bissel MD; Bloomer JR; Singal A; Gouya L; Puy H; Anderson KE; Balwani M; Phillips JD
    Mol Genet Metab; 2019 Nov; 128(3):309-313. PubMed ID: 31395332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
    Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X
    Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inheritance in erythropoietic protoporphyria].
    Schmitt C; Ducamp S; Gouya L; Deybach JC; Puy H
    Pathol Biol (Paris); 2010 Oct; 58(5):372-80. PubMed ID: 20850938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in erythrocyte protoporphyrin IX concentration by age, sex and season among patients with erythropoietic protoporphyria-20 years of follow-up.
    Heerfordt IM; Lerche CM; Wulf HC
    Photodiagnosis Photodyn Ther; 2020 Dec; 32():101928. PubMed ID: 32717453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.